Division of Nephrology, Winthrop University Hospital, Mineola, New York, USA.
J Ren Nutr. 2013 Jul;23(4):308-14. doi: 10.1053/j.jrn.2012.12.007. Epub 2013 Feb 27.
Hemodialysis (HD) patients have a high prevalence of pruritus. 25-Hydroxy vitamin D deficiency is common in this population and may play a role in its etiology. Because of this, we studied whether vitamin D2 treatment with ergocalciferol is effective for relief of uremic pruritus severity as measured by pruritus severity surveys.
DESIGN, SETTING, AND SUBJECTS: In this double-blind, placebo-controlled, randomized trial, the effect of 12 weeks of ergocalciferol administration on uremic pruritus severity was evaluated.
Fifty HD patients randomly received either ergocalciferol 50,000 international units (IU) or placebo once weekly for 12 weeks.
Pruritus severity surveys were completed every 2 weeks by all patients starting from baseline until 12 weeks and serve as the main outcome variable.
Twenty-five study participants were randomized to ergocalciferol therapy and 25 were randomized to placebo. At baseline, the only significant difference between the two groups was time on dialysis and white blood cell count. Both groups experienced a decrease in pruritus scores from the beginning to the end of study (percent change -38.9% in the treatment group vs. -47.5% in the placebo group). By intention to treat, the treatment × time effect was not statistically significant (F = 0.71, df = (1, 282), P = .34), indicating that the pruritus score was not significantly lower in the treatment group than the placebo group throughout the study.
In conclusion, we did not find ergocalciferol to be effective for the treatment of uremic pruritus.
血液透析（HD）患者瘙痒症发病率高。25-羟维生素 D 缺乏在该人群中很常见，可能在其发病机制中起作用。因此，我们研究了维生素 D2 治疗（以麦角钙化醇形式给予）是否可有效缓解瘙痒严重程度的调查评估的尿毒症瘙痒症。
设计、地点和对象：在这项双盲、安慰剂对照、随机试验中，评估了 12 周麦角钙化醇给药对尿毒症瘙痒症严重程度的影响。
50 例 HD 患者随机接受麦角钙化醇 50,000IU 或安慰剂，每周一次，共 12 周。
所有患者从基线开始，每 2 周完成一次瘙痒严重程度调查，直至 12 周，作为主要观察变量。
25 例研究参与者被随机分配到麦角钙化醇治疗组，25 例被随机分配到安慰剂组。在基线时，两组之间唯一显著的差异是透析时间和白细胞计数。两组的瘙痒评分均从研究开始到结束时均有所下降（治疗组的百分比变化为-38.9%，安慰剂组为-47.5%）。按意向治疗分析，治疗×时间的效应无统计学意义（F = 0.71，df =（1，282），P =.34），表明治疗组的瘙痒评分在整个研究过程中均不比安慰剂组低。
总之，我们没有发现麦角钙化醇对尿毒症瘙痒症的治疗有效。
